NCT03137407View on ClinicalTrials.gov

Phase 2 DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis

PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

June 12, 2017

Primary Completion Date

February 20, 2018

Study Completion Date

February 20, 2018

Conditions
Plantar Fasciitis
Interventions
BIOLOGICAL

Botulinum Toxins, Type A

Intramuscular injection

BIOLOGICAL

Placebo

Intramuscular injection

Trial Locations (5)

27157

Wake Forest Baptist Medical Center, Winston-Salem

30096

Village Podiatry Centers, Duluth

60016

Weil Foot and Ankle Institute, Des Plaines

66211

Kansas City Bone & Joint Clinic, Overland Park

78212

Element Research Group, San Antonio

All Listed Sponsors
lead

Revance Therapeutics, Inc.

INDUSTRY

NCT03137407 - Phase 2 DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis | Biotech Hunter | Biotech Hunter